Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.6.2.2 extracted from

  • Barham, H.M.; Stratford, I.J.
    Enzymology of the reduction of the novel fused pyrazine mono-N-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase (1996), Biochem. Pharmacol., 51, 829-837.
    View publication on PubMed

Application

Application Comment Organism
medicine
-
Mus musculus

Inhibitors

Inhibitors Comment Organism Structure
5-propyl-2-thiouracil 25 mM, almost complete inhibition Mus musculus
p-hydroxymercuribenzoate 0.1 mM, almost complete inhibition Mus musculus

Localization

Localization Comment Organism GeneOntology No. Textmining
endoplasmic reticulum
-
Mus musculus 5783
-

Organism

Organism UniProt Comment Textmining
Mus musculus
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
liver
-
Mus musculus
-

Specific Activity [micromol/min/mg]

Specific Activity Minimum [µmol/min/mg] Specific Activity Maximum [µmol/min/mg] Comment Organism
0.00072
-
liver microsomes, reduction of 1,2-dihydro-8-(4-methylpiperazin-1-yl)-4-phenylimidazol[3,2-e]pyrazine 5-oxide Mus musculus

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
1,2-dihydro-8-(4-methylpiperazin-1-yl)-4-phenylimidazol[3,2-e]pyrazine 5-oxide + NADH potential bioreductive drug, trivial name RB90740 Mus musculus 1,2-dihydro-8-(4-methylpiperazin-1-yl)-4-phenylimidazol[3,2-e]pyrazine + NAD+
-
?